IGC Pharma received a Notice of Allowance from the Canadian Intellectual Property Office for patent 3,095,729, which protects the proprietary composition of its Phase 2 Alzheimer’s agitation candidate IGC‑AD1. The composition combines low‑dose delta‑9 THC with a second active ingredient, a key element of the company’s strategy to deliver rapid symptom relief for agitation in Alzheimer’s disease.
The allowance was granted on February 17 2026. The company’s CALMA trial is currently 70 % enrolled and approaching final enrollment, positioning IGC‑AD1 closer to regulatory submission. The Canadian market is the largest single‑country market for Alzheimer’s therapeutics, and the patent provides a critical intellectual‑property shield in that territory.
The approval strengthens IGC Pharma’s competitive position against rivals such as Axsome and BioXcel and enhances the company’s attractiveness to potential partners and investors. CEO Ram Mukunda said, "Securing composition protection across North America strengthens the strategic foundation of IGC‑AD1 at an important stage of clinical development." He added, "As CALMA progresses toward its final enrollment phase, expanding patent coverage enhances both the durability and long‑term commercial positioning of our Alzheimer's program and supports its potential commercial differentiation."
The Canadian Alzheimer’s therapeutics market is projected to reach USD 381.9 million by 2030, while the global market is expected to grow to USD 10.11 billion by 2034. IGC Pharma’s AI‑driven discovery platform and diverse patent portfolio underpin its pipeline and support the company’s broader strategy to bring differentiated therapies to market.
The patent allowance is a milestone in IGC Pharma’s broader effort to advance IGC‑AD1 toward regulatory submission. It de‑risks the asset, supports long‑term commercial positioning, and signals progress to stakeholders. The company recently aligned its fiscal year with the calendar year to improve transparency for U.S. investors.
The approval signals a significant step forward for IGC‑AD1, positioning the candidate for future commercialization and reinforcing IGC Pharma’s strategic trajectory in the Alzheimer’s agitation space.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.